Prof. Dr. med. Peter Fasching

Professur für Translationale Frauenheilkunde und Geburtshilfe

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3 (2018) Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al. Journal article Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials (2018) Van Mackelenbergh MT, Denkert C, Nekljudova V, Karn T, Schem C, Marme F, Stickeler E, et al. Journal article MyD88 and TLR4 Expression in Epithelial Ovarian Cancer (2018) Block MS, Vierkant RA, Rambau PF, Winham SJ, Wagner P, Traficante N, Toloczko A, et al. Journal article Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study (2018) Mutschler NS, Scholz C, Friedl TWP, Zwingers T, Fasching P, Beckmann M, Fehm T, et al. Journal article Prevalence of circulating tumor cells in early breast cancer patients 2 and 5 years after adjuvant treatment (2018) Bauer ECA, Schochter F, Widschwendter P, Degregorio A, Andergassen U, Friedl TWP, Fasching P, et al. Journal article Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial (2018) Hurvitz SA, Quek RGW, Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, et al. Journal article Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab (2018) Ingle JN, Kalari KR, Wickerham DL, Von Minckwitz G, Fasching P, Furukawa Y, Mushiroda T, et al. Journal article Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients (2018) Hübner H, Fasching P, Gumbrecht W, Jud S, Rauh C, Matzas M, Paulicka P, et al. Journal article Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients (2018) Nabieva N, Kellner S, Fehm T, Häberle L, De Waal J, Rezai M, Baier B, et al. Journal article Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer (2018) Banys-Paluchowski M, Fehm T, Janni W, Aktas B, Fasching P, Kasimir-Bauer S, Milde-Langosch K, et al. Journal article